Drupal.behaviors.print = function(context) {window.print();window.close();}>
As Part of Financing Deal, Rosetta to Out-License miRNA Tech for Biofluid-Based Cancer Dx
February 02, 2012
As Part of Financing Deal, Rosetta to Out-License miRNA Tech for Biofluid-Based Cancer Dx
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Mirna Closes $34.5M Series C Round as microRNA Drugs Gain Investor Interest
October 25, 2012 / Gene Silencing News
After Raising Cash, Rosetta Aims to Restart R&D Efforts, Get Additional Medicare Approvals
October 4, 2012 / Gene Silencing News
Rosetta, Precision Therapeutics Reach Co-marketing Deal for miRview mets2 Assay
July 24, 2012 / GenomeWeb Daily News
After Medicare Nod for CUP Diagnostic, Rosetta Aims to Get Coverage for Other miRNA Tests
May 24, 2012 / Gene Silencing News
Rosetta Receives NY State Clearance for Second-Gen Test for Cancer of Unknown Primary
December 15, 2011 / Gene Silencing News